Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Publication year range
4.
Pharmacogenomics J ; 15(3): 288-92, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25348618

ABSTRACT

Cytochrome P450 3A4 (CYP3A4) is a key drug-metabolizing enzyme. Loss-of-function variants have been reported as rare events, and the first demonstration of a CYP3A4 protein lacking functional activity is caused by CYP3A4*20 allele. Here we characterized the world distribution and origin of CYP3A4*20 mutation. CYP3A4*20 was determined in more than 4000 individuals representing different populations, and haplotype analysis was performed using CYP3A polymorphisms and microsatellite markers. CYP3A4*20 allele was present in 1.2% of the Spanish population (up to 3.8% in specific regions), and all CYP3A4*20 carriers had a common haplotype. This is compatible with a Spanish founder effect and classifies CYP3A4 as a polymorphic enzyme. This constitutes the first description of a CYP3A4 loss-of-function variant with high frequency in a population. CYP3A4*20 results together with the key role of CYP3A4 in drug metabolism support screening for rare CYP3A4 functional alleles among subjects with adverse drug events in certain populations.


Subject(s)
Cytochrome P-450 CYP3A/genetics , Ethnicity/genetics , Gene Frequency/genetics , Polymorphism, Single Nucleotide/genetics , Alleles , Drug-Related Side Effects and Adverse Reactions/genetics , Founder Effect , Haplotypes/genetics , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...